Pilot Study of the Effect of Baclofen and Bromocriptine on Luteinizing Hormone Secretion in Pubertal Children
Information source: Office of Rare Diseases (ORD)
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Growth Disorders
Phase: N/A
Status: Completed
Sponsored by: National Center for Research Resources (NCRR) Official(s) and/or principal investigator(s):
Carol M. Foster, Study Chair, Affiliation: University of Michigan
Summary
OBJECTIVES: I. Evaluate the effect of bromocriptine on luteinizing hormone (LH) secretion by
suppression of prolactin and stimulation of dopaminergic receptors in early pubertal boys and
girls.
II. Evaluate the effect of baclofen on LH secretion by stimulation of gamma-aminobutyric
acid receptors in early pubertal boys and girls.
Clinical Details
Study design: Screening
Detailed description:
PROTOCOL OUTLINE:
Participants receive bromocriptine or baclofen followed by nocturnal measurements of
luteinizing hormone, growth hormone, and sex steroids. Pituitary reserve is evaluated with
the administration of gonadotropin-releasing hormone, and in children undergoing assessment
of short stature, standard provocative stimuli.
Eligibility
Minimum age: N/A.
Maximum age: 18 Years.
Gender(s): Both.
Criteria:
- Short stature and/or constitutional growth delay
- No epilepsy or risk of epilepsy
Locations and Contacts
Additional Information
Starting date: June 1995
Last updated: June 23, 2005
|
